A TheraJect MAT system is an array of rapidly dissolving micro-needles in a patch moulded from inert materials generally regarded as safe (GRAS) by the FDA, into which the active ingredient has been formulated.
Delivery to the epidermis is minimally invasive, without pain or blood. There is no “sharps” waste.
The MATTM system is capable of delivering traditional drugs or even large molecules, i.e., proteins, vaccines, genetic materials (DNA and siRNA), etc.
Current delivery profiles are rapid onset but systems can be designed to provide sustained release or patterned delivery.
Sensitive drugs or vaccines are expected to be stable at room temperature in the dry, solid state and thus systems have utility for third world applications without a “cold chain”.
Manufacturing conditions are mild and cost competitive thus can address very large existing and new markets.
This patented technology is truly enabling for a number of applications and can extend patent rights or market share for others.